Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16
Mounira Chalabi‐Dchar(Inserm), Corinne Bousquet(Centre National de la Recherche Scientifique), Muriel Mathonnet(Inserm), Florence Breibach(Pharmacochimie et Biologie pour le Développement), Mary Poupot(Centre National de la Recherche Scientifique), Shin Yonehara(Kyoto University), Catherine Roche(Centre National de la Recherche Scientifique), Hubert Lulka(Université Toulouse III - Paul Sabatier), Stéphanie Cassant‐Sourdy(Université Toulouse III - Paul Sabatier), Stéphane Pyronnet(Centre National de la Recherche Scientifique), Marie‐Bernadette Delisle(Inserm), Camille Duluc(Inserm), Rémi Samain(Inserm), Marlène Dufresne(Centre National de la Recherche Scientifique), Marjorie Fanjul(Inserm), Takeshi Shimaoka(The University of Tokyo)
Cited by 46
Related Papers
The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study
|The Lancet Neurology|2022|651
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390
Autoregulation of pituitary corticotroph SOCS-3 expression: Characterization of the murine SOCS-3 promoter
|Proceedings of the National Academy of Sciences|1999|290
Inter‐ and intra‐tumoural heterogeneity in cancer‐associated fibroblasts of human pancreatic ductal adenocarcinoma
|The Journal of Pathology|2018|284